These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 11078032)

  • 1. Efficacy, adverse events, and treatment discontinuations in fluoxetine clinical studies of major depression: a meta-analysis of the 20-mg/day dose.
    Beasley CM; Nilsson ME; Koke SC; Gonzales JS
    J Clin Psychiatry; 2000 Oct; 61(10):722-8. PubMed ID: 11078032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluoxetine versus trazodone: efficacy and activating-sedating effects.
    Beasley CM; Dornseif BE; Pultz JA; Bosomworth JC; Sayler ME
    J Clin Psychiatry; 1991 Jul; 52(7):294-9. PubMed ID: 2071559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of major depression in HIV-seropositive men. HIV Neurobehavioral Research Center Group.
    Zisook S; Peterkin J; Goggin KJ; Sledge P; Atkinson JH; Grant I
    J Clin Psychiatry; 1998 May; 59(5):217-24. PubMed ID: 9632030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of morning versus evening fluoxetine administration.
    Usher RW; Beasley CM; Bosomworth JC
    J Clin Psychiatry; 1991 Mar; 52(3):134-6. PubMed ID: 2005078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double-blind comparison of bupropion and fluoxetine in depressed outpatients.
    Feighner JP; Gardner EA; Johnston JA; Batey SR; Khayrallah MA; Ascher JA; Lineberry CG
    J Clin Psychiatry; 1991 Aug; 52(8):329-35. PubMed ID: 1907963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression.
    Feighner JP; Overø K
    J Clin Psychiatry; 1999 Dec; 60(12):824-30. PubMed ID: 10665628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features.
    Tollefson GD; Holman SL; Sayler ME; Potvin JH
    J Clin Psychiatry; 1994 Feb; 55(2):50-9. PubMed ID: 8077155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double-blind, placebo-controlled trial of nefazodone in the treatment of patients hospitalized for major depression.
    Feighner J; Targum SD; Bennett ME; Roberts DL; Kensler TT; D'Amico MF; Hardy SA
    J Clin Psychiatry; 1998 May; 59(5):246-53. PubMed ID: 9632036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluoxetine: activating and sedating effects at multiple fixed doses.
    Beasley CM; Sayler ME; Weiss AM; Potvin JH
    J Clin Psychopharmacol; 1992 Oct; 12(5):328-33. PubMed ID: 1479050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose fluoxetine: efficacy and activating-sedating effects in agitated and retarded depression.
    Beasley CM; Sayler ME; Bosomworth JC; Wernicke JF
    J Clin Psychopharmacol; 1991 Jun; 11(3):166-74. PubMed ID: 2066455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group.
    Silverstone PH; Ravindran A
    J Clin Psychiatry; 1999 Jan; 60(1):22-8. PubMed ID: 10074873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Mirtazapine-Fluoxetine Study Group.
    Wheatley DP; van Moffaert M; Timmerman L; Kremer CM
    J Clin Psychiatry; 1998 Jun; 59(6):306-12. PubMed ID: 9671343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute efficacy of fluoxetine versus sertraline and paroxetine in major depressive disorder including effects of baseline insomnia.
    Fava M; Hoog SL; Judge RA; Kopp JB; Nilsson ME; Gonzales JS
    J Clin Psychopharmacol; 2002 Apr; 22(2):137-47. PubMed ID: 11910258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gepirone extended-release: new evidence for efficacy in the treatment of major depressive disorder.
    Feiger AD; Heiser JF; Shrivastava RK; Weiss KJ; Smith WT; Sitsen JM; Gibertini M
    J Clin Psychiatry; 2003 Mar; 64(3):243-9. PubMed ID: 12716264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in adverse events reported by patients during 6 months of fluoxetine therapy.
    Zajecka J; Amsterdam JD; Quitkin FM; Reimherr FW; Rosenbaum JF; Tamura RN; Sundell KL; Michelson D; Beasley CM
    J Clin Psychiatry; 1999 Jun; 60(6):389-94. PubMed ID: 10401918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: an updated meta-analysis.
    Beasley CM; Koke SC; Nilsson ME; Gonzales JS
    Clin Ther; 2000 Nov; 22(11):1319-30. PubMed ID: 11117656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of the Hamilton Depression Rating Scale factors from a double-blind, placebo-controlled trial of fluoxetine in geriatric major depression.
    Tollefson GD; Holman SL
    Int Clin Psychopharmacol; 1993; 8(4):253-9. PubMed ID: 8277144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder.
    Alpert JE; Franznick DA; Hollander SB; Fava M
    J Clin Psychiatry; 2004 Aug; 65(8):1069-75. PubMed ID: 15323591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Citalopram treatment of fluoxetine-intolerant depressed patients.
    Calabrese JR; Londborg PD; Shelton MD; Thase ME
    J Clin Psychiatry; 2003 May; 64(5):562-7. PubMed ID: 12755660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. The Venlafaxine XR 209 Study Group.
    Thase ME
    J Clin Psychiatry; 1997 Sep; 58(9):393-8. PubMed ID: 9378690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.